1. Japan Stocks

  2. •

    Distribution services

  3. •

    Medical distributors
Vital KSK Holdings, Inc.

Vital KSK Holdings, Inc.

8.70
EUR
+0.15
(+1.75%)
Nov 09Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
9,593.51
9,623.11
11,104.96
10,311.54
10,035.97
9,931.83
10,098.72
9,745.73
10,634.65
11,153.64
11,565.04
12,242.36
12,628.71
- -
Basic EPS, GAAP
71.95
79.49
117.24
84.78
79.26
90.21
83.33
21.25
87.88
92.69
115.02
149.02
152.29
- -
Free Cash Flow per Basic Share
-277.55
90.56
-117.65
-67.3
151.71
285.49
-176.54
-94.98
61.66
-184.19
363.64
-252.06
-9
- -
Dividend per Share
16.11
16
17.95
25.96
20.02
20
23.18
24.99
11.99
26.19
46.56
44.51
58.11
- -
Book Value per Share
1,155.24
1,390.87
1,503.99
1,586.57
1,735.03
1,704.04
1,753.04
1,863.73
1,858.83
1,911.39
2,085.06
2,193.95
2,423.09
- -
Tangible Book Value per Share
1,121.11
1,262.69
1,359.57
1,454.89
1,615.38
1,601.28
1,661.4
1,780.62
1,764.24
1,846.18
2,007.11
2,105.07
2,280.73
- -
Basic Weighted Avg Shares
59
57
56
56
56
56
56
55
54
52
51
49
48
48
Sales/Revenue/Turnover
564,645
548,007
620,978
581,117
565,587
559,718
562,529
537,058
577,249
581,327
587,481
600,370
610,497
- -
Operating Margin (%)
0.57
0.33
1.11
0.55
0.42
0.5
0.63
-0.42
0.51
0.69
0.95
0.95
0.66
- -
Depreciation Expense
2,223
2,814
3,289
3,358
3,236
3,778
3,658
3,198
3,123
3,353
3,388
3,786
4,049
- -
Net Income, GAAP
4,235
4,527
6,556
4,778
4,467
5,084
4,642
1,171
4,770
4,831
5,843
7,308
7,362
- -
Effective Tax Rate (%)
38.17
28.44
34.92
29.17
29.96
32.73
34.5
46.88
36.18
39.17
31.46
30.75
35.17
- -
Profit Margin (%)
0.75
0.83
1.06
0.82
0.79
0.91
0.83
0.22
0.83
0.83
0.99
1.22
1.21
- -
Working Capital
11,694
12,095
14,398
15,009
10,075
13,190
16,766
12,208
8,440
9,843
9,896
13,016
11,686
- -
LT Debt
4,114
15,024
13,363
15,885
15,689
16,775
16,017
10,227
9,889
8,288
7,254
5,829
4,845
- -
Total Equity
67,565
78,207
85,259
90,006
98,446
96,786
97,197
103,915
100,040
100,164
105,939
107,306
118,705
- -
Return on Invested Capital (%)
2.75
1.52
4.48
2.12
1.47
1.63
2
-1.01
1.6
2.16
3.32
3.39
2.13
- -
Return on Capital (%)
5.98
5.34
6.64
4.48
3.93
4.38
3.99
0.93
4.06
4.31
5.16
6.32
6.08
- -
Return on Common Equity (%)
6.47
6.25
8.07
5.49
4.77
5.25
4.83
1.18
4.73
4.88
5.74
6.94
6.6
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
1,884
1,934
- -
LT Borrowings
4,385
3,893
- -
LT Finance Leases
- -
952
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
48
48
48
Market Capitalization
- -
- -
- -

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
201,558
194,905
- -
Cash, Cash Equivalents & STI
23,775
22,953
- -
Accounts Receivable, Net
126,365
121,233
- -
Inventories
33,482
33,283
- -
Total Current Liabilities
188,316
183,219
- -
Payables & Accruals
- -
- -
- -
ST Debt
1,884
1,934
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
3.47%
2.81%
10.62%
Free Cash Flow
-159.41%
-221.32%
-96.48%
Net Income, GAAP
25.21%
71.08%
0.74%
Sales/Revenue/Turnover
-0.1%
2.63%
1.69%
Total Cash Common Dividend
19.51%
30.24%
28.68%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
600,370
2026
- -
- -
- -
- -
610,497
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
149.02
2026
- -
- -
- -
- -
152.29
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
44.51
2026
- -
- -
- -
- -
58.11
2027
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Taisuke Murai
Full Time Employees
3,871
Sector
Distribution services
Industry
Medical distributors
Address
1-1-12, Tsurumaki Tokyo TY Japan 154-0016
IPO Date
Apr 1, 2009
Website
vitalksk.co.jp
Similar Companies
DataMeds AI, Inc. (NASDAQ:MEDS)
Selcuk Ecza Deposu Ticaret ve Sanayi A.S. (BIST:SELEC)
McKesson Corporation (NYSE:MCK)
Ibnsina Pharma (EGX:ISPH)
Cardinal Health, Inc. (NYSE:CAH)
Entero Healthcare Solutions Limited (NSE:ENTERO)
Business
Vital KSK Holdings, Inc. (3151.T) is a Japan-based holding company that engages in corporate planning and management of group companies involved in the wholesale and retail sale of pharmaceutical products; it operates primarily in the healthcare distribution sector through segments including Pharmaceutical Wholesale, Pharmacy Business, Veterinary Drug Wholesale, and other related operations. The company provides general wholesale of medical pharmaceuticals, clinical test reagents, veterinary drugs, medical devices, vaccines, sanitary materials, serums, poisonous or deleterious substances, narcotics, quasi-drugs, paints, pigments, dyes, medical equipment, hygiene goods, nursing care products, and beverages to hospitals, medical institutions, pharmacies, nursing care facilities, farms, ranches, and veterinary clinics; its Pharmacy Business operates community-based stores offering remote medication guidance, clean benches, and medication lockers in compliance with Pharmaceuticals and Medical Devices Act amendments; the Veterinary Drug Wholesale Business supports livestock farmers and pet health through veterinary medicines and feed; additional services encompass agrochemical wholesale via VITAL-GREEN, INC., nursing care support, medical and pharmacy consulting through Health Care Management Institute, Ltd., general freight transportation, insurance agency, real estate management, and sports facility operations. Founded on April 1, 2009, through the merger of VITAL-NET, INC. and KSK Co., Ltd., Vital KSK Holdings maintains its headquarters at 1-1-12 Tsurumaki, Setagaya-ku, Tokyo, Japan, and employs 3,705 consolidated staff as of the fiscal year ended March 31, 2024, with net sales of 87,471 million yen; it lists on the Tokyo Stock Exchange Prime Market and focuses on community-based networks across Japan to enhance social infrastructure for health protection. Recent developments include recording a gain on sale of investment securities totaling 3,235 million yen by subsidiaries in December 2024 as extraordinary income; a subsidiary's initiation of a Phase II clinical trial in Japan for ACCRUFER (ferric maltol) as a treatment for Pulmonary Arterial Hypertension; share repurchases and updates to large shareholder status; revisions to FY2025 financial forecasts reflecting decreased sales offset by higher investment returns; and consolidated financial results announcements for interim periods ending September 2024 and beyond, alongside ongoing enhancements in pharmacy compliance and logistics efficiency.